Real-world management of patients with complete response under immune-checkpoint inhibition for advanced melanoma.

ABSTRACT:

Background

Up to now, the optimal duration of immune checkpoint inhibitors (ICI) has not been evaluated in prospective studies. However, current clinical practice requires decisions to be made regarding the duration of ICI in complete responders.

Material and methods

A survey was sent to 80 DeCOG skin cancer centers to assess how decisions are made on treatment duration of ICI in melanoma after having reached complete response, and staging intervals after ICI discontinuation. All responses received by March 10, 2024 (51 centers) were included.

Results

The duration of ICI after having achieved complete remission varies between centers from three to 36 months. In total, 66% of the DeCOG centers continue treatment for up to 6 months, after having achieved complete remiss

SUBMITTER: Reitmajer M 

PROVIDER: S-EPMC11887019 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature